The preliminary outcomes of the 10th round of China’s national volume-based procurement (VBP) program were released, with a total of 195 drug manufacturers securing tender spots for 62 different drug products. There were no failed tenders in this round, and the official results are anticipated to be announced after December 16, barring any objections.
Leading Bidders and Price Reductions
Among the leading bid winners, Kelun Pharma, CSPC, and Brilliant Pharma shared the top ranking with 15 bids each. CR Pharma followed with 10 successful bids, while Qilu Pharma and Fosun Pharma each had eight bids accepted. The winning bids recorded an average of 73% price cuts, marking a record high since the cancellation of the bid-winning rule that required a price reduction of at least 50% compared to the maximum valid limit price.
Foreign Participation and Success
The only foreign winner in this round is Ukraine-based Farmak, with its gadoteric acid meglumine salt, a contrasting agent that received marketing approval in China on December 1, 2024, which was also the VBP filing cut-off date. No other foreign manufacturers or originator companies were successful in securing a tender spot in this round.-Fineline Info & Tech
